Roche

What Roche does

Roche South Africa is the wholly-owned local subsidiary of F. Hoffmann-La Roche Ltd, the Swiss multinational pharmaceutical and diagnostics company founded in 1896. The South African entity operates through three core business divisions: Pharmaceuticals, Diagnostics, and Diabetes Care, headquartered in Midrand with postal operations in Halfway House. Its pharmaceutical portfolio spans oncology (breast, lung, liver, skin, haematological cancers), neuroscience (multiple sclerosis, NMOSD, Alzheimer's, Parkinson's, SMA), respiratory disease (IPF), ophthalmology, infectious diseases, inflammatory bowel disease, cardiometabolic disease, and women's health. The diagnostics division supplies Cobas laboratory instrumentation, molecular and tissue diagnostics, point-of-care testing, haematology, hemostasis, urinalysis, and blood safety solutions, supported by recurring reagent and consumable revenue. Diabetes Care delivers Accu-Chek glucose monitors (Instant, Performa), Accu-Chek Combo insulin delivery, and the Eversense implantable continuous glucose monitoring system. Roche's proprietary technology stack centres on biomarker testing and genomic profiling to enable personalized treatment selection, complemented by AI-powered diagnostic capabilities deployed in partnership with Medsol AI for breast cancer detection at primary care level.

The business model combines multi-year institutional tenders and government contracts for pharmaceuticals and diagnostics equipment (priced per unit or under enterprise agreements), direct-to-pharmacy distribution for prescription medicines, and recurring consumables/reagents revenue from installed Cobas and Accu-Chek bases. Go-to-market operates through dedicated disease-area field sales squads (oncology, haemophilia, breast cancer, ophthalmology), event-driven engagement at medical congresses (ESMO Africa, OSSA, WFH), and community-led partnerships through Unjani Clinics, PinkDrive mobile screening, and the long-running Phelophepa Health Train sponsorship (since 1994). Customers include public academic hospitals, private hospital groups, independent laboratories, healthcare professionals, and ultimately patients across South Africa. Under the 'One Roche' Pan-African strategy, the SA entity coordinates oncology, diagnostics, and access initiatives with affiliates in Ghana, Kenya, and Nigeria.

The company pursues growth through an ecosystem-buildout strategy that combines strategic clinical partnerships (BIGOSA founding partner for eight standardized breast cancer centres over 30 months), AI diagnostic partnerships (Medsol AI), community screening scale-up, and pan-African commercial coordination. The model is partnership-intensive rather than purely transactional, anchoring Roche in policy alignment with the National Department of Health (haemophilia real-world data, 2017 Breast Cancer Guidelines), global bodies (UICC, World Federation of Haemophilia), and on-the-ground delivery partners, positioning the subsidiary as both a pharmaceutical supplier and a healthcare system shaper in Southern Africa.

Name

Roche

Legal name

F. Hoffmann-La Roche Ltd

Website

https://roche.co.za

Company type

Public

Founded year

1896

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Roche South Africa is the local subsidiary of Swiss pharmaceutical and diagnostics giant F. Hoffmann-La Roche Ltd, operating Pharma, Diagnostics, and Diabetes Care divisions. It supplies innovative medicines, Cobas laboratory diagnostics, and Accu-Chek glucose monitors to public hospitals, private groups, and community clinics across South Africa and the broader Pan-African region.

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Diagnostics

NAICS

Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Pharmaceutical medicines
• In-vitro diagnostics
• Clinical laboratory equipment
• Diabetes care devices
• Personalised healthcare

Headquarters

HQ city

Midrand

HQ country

South Africa

HQ region

Africa

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical Products: Roche develops and sells innovative medicines across multiple therapeutic areas including oncology, neuroscience, immunology, infectious diseases, and haematology
2. Diagnostics Products and Services: Roche Diagnostics provides comprehensive diagnostic solutions including Cobas machines, haematology, urinalysis, molecular diagnostics, tissue diagnostics, and point of care testing. The Diabetes Care division provides glucose monitoring systems including Accu-Chek products
3. Healthcare Support Services: Roche provides support to healthcare organisations and patient groups through grants, sponsorships and donations for health initiatives, campaigns and educational programmes

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

Roche develops and sells innovative pharmaceutical medicines across oncology, neuroscience, immunology, infectious diseases, and haematology, and provides comprehensive diagnostic solutions through Cobas laboratory instruments, molecular/tissue diagnostics, point-of-care testing, and reagents. A Diabetes Care division sells Accu-Chek glucose monitors, Accu-Chek Combo insulin delivery systems, and the Eversense continuous glucose monitoring system to healthcare institutions, laboratories, and pharmacy channels across Southern Africa.

Product overview

Roche operates as a research-based healthcare company with two primary divisions: Pharmaceuticals and Diagnostics. The pharmaceutical division develops innovative medicines across multiple therapeutic areas including oncology (breast cancer, lung cancer, liver cancer, skin cancer, haematology), neuroscience (multiple sclerosis, Alzheimer's, Parkinson's, NMOSD, SMA, DMD), respiratory diseases (IPF), infectious diseases, inflammatory bowel diseases, cardiometabolic diseases, and women's health. The Diagnostics division provides a comprehensive portfolio including Cobas laboratory instruments, point-of-care testing, molecular diagnostics, tissue diagnostics, haematology, hemostasis testing, and urinalysis solutions. Diabetes Care products include Accu-Chek glucose meters (Instant, Performa), Accu-Chek Combo insulin delivery system, and the Eversense continuous glucose monitoring system. Roche South Africa also supports community healthcare through initiatives like the Phelophepa Health Train and various breast cancer awareness programs.

Differentiator

Problem solved

Functional benefit

Brands

• Roche Pharma: Pharmaceutical division focusing on innovative medicines for oncology, haematology, neuroscience, and other therapeutic areas
• Roche Diagnostics
• Roche Diabetes Care
• Accu-Chek
• Cobas

Products and services

• Cobas laboratory diagnostic systems Automated clinical laboratory instrumentation platforms covering clinical chemistry, immunochemistry, molecular diagnostics, point-of-care testing, and tissue diagnostics, sold to hospital and independent laboratories under multi-year enterprise agreements.
• Diagnostic reagents and consumables Reagents and consumables used with Cobas and other Roche diagnostic platforms across immunochemistry, clinical chemistry, molecular, tissue, haematology, urinalysis, haemostasis, and point-of-care testing.
• Roche Blood Safety Solutions Blood screening solutions for pathogen detection to support safe blood supply, offered through the diagnostics division to blood banks and transfusion services.
• Accu-Chek Instant blood glucose monitor Self-monitoring blood glucose meter with instant result display and easy-to-use interface, distributed through pharmacy channels for people with diabetes.
• Accu-Chek Performa blood glucose meter Blood glucose meter designed for accurate and reliable glucose testing as part of daily diabetes management.
• Accu-Chek Combo insulin delivery system Insulin pump system combined with blood glucose monitoring for integrated insulin delivery and glucose management in diabetes care.
• Eversense Continuous Glucose Monitoring System Long-term implantable continuous glucose monitoring system providing ongoing glucose data for diabetes management.

Quantifiable outcome

• South African public sector breast cancer survival rate of 44%, with initiative targeting significant improvement through standardised breast centres
• +2 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature3 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Breast Interest Group of Southern Africa (BIGOSA)coreStrategic or Co-development Partner · 1 January 2026Roche serves as founding partner for BIGOSA's initiative to establish a network of standardised, specialised breast cancer centres across South Africa. The initiative aims to improve the 44% public sector breast cancer survival rate through structured, multidisciplinary care delivered through at least eight breast centres over 30 months, involving both public and private hospital partners.
• Unjani Clinic NetworkcoreStrategic or Co-development PartnerPartnership supporting community healthcare delivery through a network of nurse-led primary healthcare clinics. Roche supports early detection and screening initiatives, particularly for women's breast cancer, through this community-based healthcare network serving peri-urban communities.
• PinkDrivecoreStrategic or Co-development PartnerCorporate partnership supporting PinkDrive's mobile cancer screening programme delivering mammograms, pap smears, HPV testing, and PSA tests to communities nationwide. The partnership enables earlier detection and more equitable cancer care across South Africa.
• Medsol AIcoreTechnology or IntegrationAI technology partnership deploying artificial intelligence for breast cancer early diagnosis at primary care clinics. Medsol AI's technology brings specialist-level accuracy to resource-limited settings, multiplying the reach of diagnostic capabilities in underserved communities.
• Union for International Cancer Control (UICC)coreStrategic or Co-development PartnerLong-term partnership since 2008 to reduce the global cancer burden and improve patient lives. Roche is lead industry partner for UICC's City Cancer Challenge, working with cities to develop and pilot engagement models for sustainable cancer care. Also a long-time supporter of World Cancer Day.
• Phelophepa Health TraincoreStrategic or Co-development PartnerRoche has been the key sponsor of the Roche healthcare clinic on the Phelophepa train since 1994. The train travels 35 weeks per year, visiting one rural community a week and has brought healthcare services to millions of people across South Africa.
• Africa Health VenturesminorGTM or Marketing PartnerPodcast partnership hosting the Africa Health Ventures Podcast series addressing critical challenges in African breast cancer care and exploring AI deployment for early diagnosis at primary care clinics.
• World Federation of Haemophilia (WFH)coreStrategic or Co-development PartnerParticipation in WFH Congress providing South African healthcare professionals opportunities to engage with global experts, emerging evidence, and evolving approaches to haemophilia care. Initiative to translate global innovation into local impact.
• Charlotte Maxeke Johannesburg Academic HospitalcoreStrategic or Co-development PartnerPublic sector partner in BIGOSA breast centre network initiative, contributing to the development of standardised breast cancer care centres in South Africa.
• Chris Hani Baragwanath HospitalcoreStrategic or Co-development PartnerPublic sector partner in BIGOSA breast centre network initiative, one of Africa's largest hospitals contributing to standardised breast cancer care development.
• Groote Schuur HospitalcoreStrategic or Co-development PartnerPublic sector partner in BIGOSA breast centre network initiative, contributing expertise to the development of breast cancer centres of excellence.
• Mediclinic GroupcoreStrategic or Co-development PartnerPrivate sector partner in BIGOSA breast centre network initiative, bringing private healthcare expertise to the standardised breast cancer care development.
• LenMed GroupcoreStrategic or Co-development PartnerPrivate sector partner in BIGOSA breast centre network initiative, contributing to the expansion of standardised breast cancer care across South Africa.
• Busamed GroupcoreStrategic or Co-development PartnerPrivate sector partner in BIGOSA breast centre network initiative, participating in the development of breast cancer centres of excellence.
• National Department of Health (South Africa)coreStrategic or Co-development PartnerCollaboration with NDoH to support collection of real-world data and evidence for haemophilia care and alignment with government policy including 2017 National Department of Health Breast Cancer Guidelines.
• Ophthalmological Society of South Africa (OSSA)coreStrategic or Co-development PartnerRoche demonstrated presence at OSSA Congress, engaging with international retinal experts and local ophthalmologists through 'Meet the Expert' sessions and symposiums to advance local retinal care.
• Moorfields Eye Hospital (UK)minorStrategic or Co-development PartnerInternational retinal expert Professor Robin Hamilton from Moorfields Eye Hospital engaged through OSSA Congress to bridge international clinical trial outcomes with South African practice.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Abbott: Operates both a pharmaceutical/medical-products business and a major diagnostics division, paralleling Roche's integrated pharma-diagnostics structure. Overlaps with Roche in point-of-care diagnostics, lab instruments, and diabetes care.
• Siemens Healthineers: Major diagnostics competitor offering laboratory instrumentation, immunoassays, and point-of-care testing that directly overlaps with Roche's Cobas platform and central-lab diagnostics business.
• Sanofi: Pharmaceutical major with strong immunology (Dupixent), oncology, and rare disease franchises that compete with Roche's immunology and specialty areas. Comparable emerging-market distribution model and branded-innovator positioning.
• Merck & Co. (MSD): Major oncology competitor (Keytruda) with comparable neuroscience and vaccine franchises. Operates a similar branded-innovator pharmaceutical model across multiple therapeutic categories, making it a core direct peer to Roche's pharma division.
• Bristol-Myers Squibb: Oncology-focused pharmaceutical major (immuno-oncology, haematology) competing directly with Roche in breast cancer, lung cancer, and haematological malignancies across global and emerging markets.
• AstraZeneca: Oncology-led pharmaceutical major with strong respiratory, cardiovascular, and rare-disease franchises. Its emerging-market commercial model and therapeutic-area breadth directly parallel Roche's go-to-market approach in Sub-Saharan Africa.
• Novartis: Global pharmaceutical leader with overlapping therapeutic areas including oncology, neuroscience, and cardiovascular. Novartis's combination of innovative medicines and diagnostics-adjacent capabilities makes it a direct comparable to Roche's integrated pharma-diagnostics model.
• Pfizer: Global pharmaceutical giant with oncology, infectious disease, and neuroscience franchises comparable to Roche's portfolio breadth. Competes head-to-head in hospital-channel sales across Southern Africa and other emerging markets.

Broad incumbents

• Bayer: Diversified life sciences incumbent with pharmaceutical and consumer health divisions. Comparable in women's health, oncology, and cardiovascular therapeutics, though Bayer's broader portfolio makes it a wider competitor rather than direct niche overlap.
• GSK: Diversified pharmaceutical and vaccines incumbent with overlapping respiratory, oncology, and infectious disease franchises. Operates as a broader incumbent rather than a focused Roche-comparable in oncology diagnostics.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/roche
• YouTubeyoutube.com/roche
• Facebookfacebook.com/roche
• LinkedInlinkedin.com/company/roche
• Instagraminstagram.com/roche

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Roche